IQVIA Holdings Inc. (NYSE:IQV) Stock Has Average Price Target of $248.00 According to Brokerages

IQVIA Holdings Inc. (NYSE:IQV) has been given a consensus recommendation of “Moderate Buy” by the seventeen ratings firms that are currently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $248.00.

IQV has been the topic of several recent research reports. Morgan Stanley lifted their target price on shares of IQVIA from $240.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, September 17th. Royal Bank Of Canada lifted their price target on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. HSBC restated a “buy” rating and set a $240.00 price objective on shares of IQVIA in a research report on Monday, July 6th. Finally, Mizuho upped their price objective on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, July 13th.

IQVIA Price Performance

Shares of IQV opened at $275.38 on Friday. IQVIA has a 12-month low of $154.50 and a 12-month high of $277.40. The business has a 50-day simple moving average of $247.71 and a two-hundred day simple moving average of $202.28. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock has a market cap of $45.33 billion, a PE ratio of 34.17, a PEG ratio of 2.31 and a beta of 1.18.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period last year, the firm posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts anticipate that IQVIA will post 11.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other IQVIA news, insider W. Richard Staub sold 5,500 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the sale, the insider owned 13,312 shares in the company, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the sale, the insider owned 2,989 shares in the company, valued at $732,932.69. This represents a 15.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 15,581 shares of company stock valued at $3,796,021. 1.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Financial Freedom LLC bought a new position in IQVIA during the 1st quarter valued at $25,000. Ascentis Independent Advisors bought a new position in shares of IQVIA during the 1st quarter worth approximately $25,000. Compass Financial Management LLC purchased a new stake in shares of IQVIA during the second quarter valued at approximately $27,000. Elevation Wealth Partners LLC boosted its position in IQVIA by 218.8% in the second quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company’s stock worth $30,000 after purchasing an additional 105 shares during the last quarter. Finally, Caitlin John LLC bought a new stake in shares of IQVIA during the 2nd quarter worth $31,000. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.